REG - Hikma Pharmaceutical - Hikma announces CEO change and Board appointment

Hikma PharmaceuticalsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO4766La&default-theme=true

RNS Number : 4766L  Hikma Pharmaceuticals Plc  15 December 2025

Hikma announces CEO change and Board appointment

 

This announcement contains inside information

 

London, 15 December 2025 - Hikma Pharmaceuticals PLC (Hikma) announces that
Riad Mishlawi is today stepping down as Chief Executive Officer (CEO) and from
Hikma's Board of Directors by mutual agreement.

Said Darwazah, Hikma's Executive Chairman and former CEO, will assume all CEO
responsibilities with immediate effect.  In addition, Khalid Nabilsi, Hikma's
Chief Financial Officer, will join Hikma's Board of Directors and take on
additional management responsibilities to further strengthen the Group's focus
on delivering its strategic plans.

Said Darwazah said: "I would like to thank Riad for his contributions over his
long career at Hikma and we wish him well for the future.  I look forward to
continuing to work closely with Hikma's Executive Committee and with Khalid in
his expanded role to deliver on our strategic plans."

Victoria Hull, Hikma's Senior Independent Director said: "The Board is
confident in Hikma's future growth prospects under the experienced leadership
of Said, supported by Hikma's talented global team.  We will be launching a
search for a new CEO in due course."

Riad Mishlawi said: "I'd like to thank Said and all my Hikma colleagues.  It
has been an honour to work alongside you and, as I move into retirement, I
wish you continued growth and every success."

Group guidance for 2025 remains unchanged from the 6 November 2025 trading
update and Hikma will report its 2025 full year results on 26 February 2026.

 

Notes:

 

The person responsible for the release of this announcement on behalf of Hikma
is Helen Middlemist (Company Secretary).

 

Hikma confirms there is no information required to be disclosed in relation to
Khalid Nabilsi's appointment as a director pursuant to UK Listing Rule 6.4.8R.

 

Details of remuneration arrangements in relation to Riad Mishlawi's departure
from Hikma will be disclosed on Hikma's website in accordance with section
430(2B) of the Companies Act 2006.

 

--  ENDS  --

 

Enquiries:

Hikma
(Investors)

 Susan Ringdal                                                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations

 FTI Consulting (Media)

 Ciara Martin

                                                                              +44 (0)7779 775979

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,500 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

©2025 Hikma Pharmaceuticals PLC. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPGAWPUPAGQC



            Copyright 2019 Regulatory News Service, all rights reserved